Medicaid Programs Must Cover Aduhelm, CMS Says; Accelerated Approval Criticisms Sticking Broadly For All Drugs When It Comes To Reimbursement

Prevision Policy Clips | JAK Inhibitor Reviews Resume: Incyte Opzelura (Topical Ruxolitinib) Approved By FDA With Boxed Warning

BsUFA III Agreement Revamps Biosimilar Supplement Review Timelines; FDA Gets 10% Raise To Support 15 New FTEs

Prevision Policy Clips | BsUFA III Agreement Set For Public Review At Nov. 2 Meeting

Drug Development “Snapshots” To Expedite “Breakthrough” Communication Proposed By FOCR Working Group; Dosing Could Be Good Starting Point For Pilot Tests, FDA Suggests

Pfizer/BioNTech COVID-19 Boosters Nearly End In Complete Failure; CBER’s Marks Helps To Salvage Application With A Narrowed Indication – But At What Cost?

Prevision Policy Clips | Pfizer Announces Positive Data For COVID-19 Vaccine In 5-11 Year Olds; EUA Submission Planned “As Soon As Possible”

Prevision Policy Clips | Biosimilars Q&A Guidance Finalized: FDA Transfers Some Questions, Withdraws Others

Gene Therapy Sponsors Engage In FDA Safety Review: Pfizer Describes Enhanced Lab Monitoring For DMD Therapy To CBER Committee

Prevision Policy Clips | HR3 Fails In Committee; Now The Real Negotiations Begin?

Pfizer/BioNTech COVID-19 Booster Advisory Committee Will Air FDA Internal Disputes: Briefing Documents Advise Caution, While Leadership Favors Approval

FDA/EMA Launch Parallel Scientific Advice Program For Complex Generics; “Clearer Understanding” Of Regulatory Requirements Is Key Goal

Prevision Policy Clips | Will HR 3 Survive Mark-Up? Energy & Commerce Considers Drug Pricing Provisions Today

FDA/PTO Collaboration At Examiner Level May Be Long-Term Impact Of Biden Competition Plan To Address Drug Patents

Prevision Policy Clips | CMS Abandons Plan To Consider Commercial Market In Determining Part B Coverage Policies

Reconciliation Scorecard: House Democrats Start With $600 Billion-Plus Hit To Pharma; Negotiation Is Not The Only Provision To Watch

Prevision Policy Clips | FDA Vaccine Division Leaders Oppose Routine COVID Booster Dose At This Time, Lancet Article Indicates

Prevision Policy Clips | Federal Medicaid Program, HR3 Provisions Included In House Energy & Commerce Budget Reconciliation Package

Medicare Part B Demos Outlined By HHS In Low-Profile Drug Pricing Report; Biosimilars Are A Prominent Theme: Safe Terrain For Industry If Price Negotiation Push Fails?

Prevision Policy Clips | House Reconciliation Bill Mark-Ups Begin: Health Care Expansion On Ways & Means Agenda This Week

Mandatory Opioid Prescriber Education Gets Another Look; FDA Reconsiders Required Training As Part Of REMS

Prevision Policy Clips | FDA’s Cellular, Tissue and Gene Therapies Advisory Committee Recommended Against Setting A Strict Dosing Ceiling

FDA Launches Novel Excipient Review Pilot; Four New Inactive Ingredients Will Be Reviewed In First Two Years

Gene Therapy Dosing Caps Not Recommended By FDA Advisory Committee, But Standards Urged To Address “Empty” Capsids And Potential Toxicity

A User’s Guide To PDUFA VII: New Agreement Carries Forward PDUFA VI Priorities And Layers On New Projects; New Work Comes With Larger New Staff Support